3-O-Methyldopa and the response to levodopa in Parkinson's disease

John Nutt, William Woodward, S. T. Gancher, D. Merrick

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Plasma 3-O-methyldopa (3OMD) concentrations in parkinsonian patients treated with levodopa on a long-term basis reflect daily levodopa dosage and do not vary markedly during the day. Oral challenges with 3OMD reduce the clinical response to levodopa infusions, but 3OMD is no more potent than phenylalanine in this regard. These observations, plus the fact that 3OMD makes a small contribution to the total concentration of large neutral animo acids competing with levodopa for transport at the blood-brain barrier, support the contention that 3OMD is not an important determinant of clinical response to levodopa.

Original languageEnglish (US)
Pages (from-to)584-588
Number of pages5
JournalAnnals of Neurology
Volume21
Issue number6
StatePublished - 1987

Fingerprint

Levodopa
Parkinson Disease
Blood-Brain Barrier
Phenylalanine
3-O-methyl-DOPA
Acids

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

3-O-Methyldopa and the response to levodopa in Parkinson's disease. / Nutt, John; Woodward, William; Gancher, S. T.; Merrick, D.

In: Annals of Neurology, Vol. 21, No. 6, 1987, p. 584-588.

Research output: Contribution to journalArticle

Nutt, John ; Woodward, William ; Gancher, S. T. ; Merrick, D. / 3-O-Methyldopa and the response to levodopa in Parkinson's disease. In: Annals of Neurology. 1987 ; Vol. 21, No. 6. pp. 584-588.
@article{0cd0af54555442c7b5709b9e5877428d,
title = "3-O-Methyldopa and the response to levodopa in Parkinson's disease",
abstract = "Plasma 3-O-methyldopa (3OMD) concentrations in parkinsonian patients treated with levodopa on a long-term basis reflect daily levodopa dosage and do not vary markedly during the day. Oral challenges with 3OMD reduce the clinical response to levodopa infusions, but 3OMD is no more potent than phenylalanine in this regard. These observations, plus the fact that 3OMD makes a small contribution to the total concentration of large neutral animo acids competing with levodopa for transport at the blood-brain barrier, support the contention that 3OMD is not an important determinant of clinical response to levodopa.",
author = "John Nutt and William Woodward and Gancher, {S. T.} and D. Merrick",
year = "1987",
language = "English (US)",
volume = "21",
pages = "584--588",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - 3-O-Methyldopa and the response to levodopa in Parkinson's disease

AU - Nutt, John

AU - Woodward, William

AU - Gancher, S. T.

AU - Merrick, D.

PY - 1987

Y1 - 1987

N2 - Plasma 3-O-methyldopa (3OMD) concentrations in parkinsonian patients treated with levodopa on a long-term basis reflect daily levodopa dosage and do not vary markedly during the day. Oral challenges with 3OMD reduce the clinical response to levodopa infusions, but 3OMD is no more potent than phenylalanine in this regard. These observations, plus the fact that 3OMD makes a small contribution to the total concentration of large neutral animo acids competing with levodopa for transport at the blood-brain barrier, support the contention that 3OMD is not an important determinant of clinical response to levodopa.

AB - Plasma 3-O-methyldopa (3OMD) concentrations in parkinsonian patients treated with levodopa on a long-term basis reflect daily levodopa dosage and do not vary markedly during the day. Oral challenges with 3OMD reduce the clinical response to levodopa infusions, but 3OMD is no more potent than phenylalanine in this regard. These observations, plus the fact that 3OMD makes a small contribution to the total concentration of large neutral animo acids competing with levodopa for transport at the blood-brain barrier, support the contention that 3OMD is not an important determinant of clinical response to levodopa.

UR - http://www.scopus.com/inward/record.url?scp=0023265840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023265840&partnerID=8YFLogxK

M3 - Article

C2 - 3606046

AN - SCOPUS:0023265840

VL - 21

SP - 584

EP - 588

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -